Gaurav Jain

Dr. Gaurav Jain

Center for Advanced Formulation Technology, Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi 110017, India

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in Saudi Pharmaceutical Journal
Verified
Journal Article
Open access
AMAbdul Muheem
Abdul Muheem
FSFaiyaz Shakeel
Faiyaz Shakeel
MJMohammad Asadullah Jahangir
Mohammad Asadullah Jahangir
MAMohammed Anwar
Mohammed Anwar
NMNeha Mallick
Neha Mallick
FAFarhan Jalees Ahmad
Farhan Jalees Ahmad
In the modern world, a number of therapeutic proteins such as vaccines, antigens, and hormones are being developed utilizing different sophisticated biotechnological techniques like recombinant DNA technology and protein purification. However, the major glitches in the optimal utilization of therapeutic proteins and peptides by the oral route are their extensive hepatic first-pass metabolism, degradation in the gastrointestinal tract (presence of enzymes and pH-dependent factors), large molecular size and poor permeation. These problems can be overcome by adopting techniques such as chemical transformation of protein structures, enzyme inhibitors, mucoadhesive polymers and permeation enhancers. Being invasive, parenteral route is inconvenient for the administration of protein and peptides, several research endeavors have been undertaken to formulate a better delivery system for proteins and peptides with major emphasis on non-invasive routes such as oral, transdermal, vaginal, rectal, pulmonary and intrauterine. This review article emphasizes on the recent advancements made in the delivery of protein and peptides by a non-invasive (peroral) route into the body.

16 July 2010 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
Mohammad Zaki AhmadMohammad Zaki Ahmad
Mohammad Zaki Ahmad
SASohail Akhter
Sohail Akhter
Gaurav JainGaurav Jain
Gaurav Jain
MRMahfoozur Rahman
Mahfoozur Rahman
SPShadab Ahmad Pathan
Shadab Ahmad Pathan
RKRoop Krishen Khar
Roop Krishen Khar
(2010). Metallic nanoparticles: technology overview & drug delivery applications in oncology. Expert Opinion on Drug Delivery: Vol. 7, No. 8, pp. 927-942. doi: 10.1517/17425247.2010.498473

1 November 2008 in Drug Discovery Today
Verified
Journal Article
Closed access
NJNilu Jain
Nilu Jain
Gaurav JainGaurav Jain
Gaurav Jain
SJShamama Javed
Shamama Javed
ZIZeenat Iqbal
Zeenat Iqbal
STSushama Talegaonkar
Sushama Talegaonkar
RKRoop K. Khar
Roop K. Khar

1 January 2009 in Recent Advances in Drug Delivery and Formulation
Verified
Journal Article
Closed access
SPShadab Pathan
Shadab Pathan
ZIZeenat Iqbal
Zeenat Iqbal
SZSyed Zaidi
Syed Zaidi
STSushama Talegaonkar
Sushama Talegaonkar
DVDivya Vohora
Divya Vohora
FAFarhan Jalees Ahmad
Farhan Jalees Ahmad
The brain is a delicate organ, and nature has very efficiently protected it. The brain is shielded against potentially toxic substances by the presence of two barrier systems: the blood brain barrier (BBB) and the blood cerebrospinal fluid barrier (BCSFB). Unfortunately, the same mechanisms that protect it against intrusive chemicals can also frustrate therapeutic interventions. Despite aggressive research, patients suffering from fatal and/or debilitating central nervous system (CNS) diseases, such as brain tumours, HIV encephalopathy, epilepsy, cerebrovascular diseases and neurodegenerative disorders, far outnumber those dying of all types of systemic cancers or heart diseases. The abysmally low number of potential therapeutics reaching commercial success is primarily due to the complexity of the CNS drug development. The clinical failure of many probable candidates is often, ascribable to poor delivery methods which do not pervade the unyielding BBB. It restricts the passive diffusion of many drugs into the brain and constitutes a significant obstacle in the pharmacological treatment of central nervous system (CNS) disorders. General methods that can enhance drug delivery to the brain are, therefore, of great pharmaceutical interest. Various strategies like non-invasive methods, including drug manipulation encompassing transformation into lipophilic analogues, prodrugs, chemical drug delivery, carrier-mediated drug delivery, receptor/vector mediated drug delivery and intranasal drug delivery, which exploits the olfactory and trigeminal neuronal pathways to deliver drugs to the brain, are widely used. On the other hand the invasive methods which primarily rely on disruption of the BBB integrity by osmotic or biochemical means, or direct intracranial drug delivery by intracerebroventricular, intracerebral or intrathecal administration after creating reversible openings in the head, are recognised. Extensive review pertaining specifically, to the patents relating to drug delivery across the CNS is currently available. However, many patents e.g. US63722506, US2002183683 etc., have been mentioned in a few articles. It is the objective of this article to expansively review drug delivery systems for CNS by discussing the recent patents available.

19 October 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ASAmit Sah
Amit Sah
PNPunnoth Poonkuzhi Naseef
Punnoth Poonkuzhi Naseef
MKMohamed Saheer Kuruniyan
Mohamed Saheer Kuruniyan
Gaurav JainGaurav Jain
Gaurav Jain
FZFoziyah Zakir
Foziyah Zakir
GAGeeta Aggarwal
Geeta Aggarwal
Chamomile has a long history of traditional medicinal uses. The two commonly used varieties with therapeutic applications are German chamomile known as Matricaria chamomilla L. and Roman chamomile or Chamaemelum nobile L. The plant contains many components, namely, flavonoids, terpenoids, and coumarins, which are responsible for its medicinal properties. The review discusses recent developments that help in establishing its role as a therapeutic agent in various areas as an anti-inflammatory, antioxidant, analgesic, antimicrobial, hepatoprotective, anti-allergic, anticancer, and anti-hypertensive agent. Not much is known about its role in the treatment of CNS disorders and metabolic syndromes, which are also discussed. The chemical components responsible for the therapeutic activity and the respective mechanism of action are also elaborated.

8 February 2016 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
AMAsiya Mahtab
Asiya Mahtab
MAMohammed Anwar
Mohammed Anwar
NMNeha Mallick
Neha Mallick
ZNZrien Naz
Zrien Naz
Gaurav JainGaurav Jain
Gaurav Jain
FAFarhan Jalees Ahmad
Farhan Jalees Ahmad